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HoBACKGROUND The results of SYNTAX trial have been reported based on “corelab” calculated SS (cSS). It has been
shown that reproducibility of SS is better among the core laboratory technicians than interventional cardiologists.
Thus, the prognostic value and clinical implication of the “site” SYNTAX SS (sSS) remain unknown.
OBJECTIVES The study sought to evaluate the prognostic value and clinical implication of the sSS after percutaneous
coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery in the randomized SYNTAX trial.
METHODS The sSS was calculated by the site investigators before randomization in the SYNTAX trial. New tertiles based
on the sSS were deﬁned with low (0 to 19), intermediate (20 to 27), and high ($28) scores. The clinical endpoints were
compared between PCI and CABG by Kaplan-Meier estimates, log-rank comparison, and Cox regression analyses using the
new tertiles. The sSS-based SS II was calculated and its predictive performance was evaluated.
RESULTS The mean difference in cSS and sSS is 3.8  11.2, with a mean absolute difference of 8.9  7.8. In the overall
cohort, using sSS there was a higher incidence of major adverse cardiac and cerebrovascular events (MACCE) at 5-year
follow-up in the PCI group for low (31.9% vs. 24.5%; p ¼ 0.054), intermediate (39.5% vs. 29.5%; p ¼ 0.019), and high
(43.0% vs. 31.4%; p ¼ 0.003) tertiles, compared with the CABG group. Similarly, in the 3-vessel disease subgroup,
5-year MACCE rates were higher in PCI group in all tertiles. Conversely, in the left main subgroup, MACCE rates were
similar for PCI and CABG groups in all tertiles. The sSS-based SS II (c-index: 0.736) had predictive performance similar
to the cSS-based SS II (c-index: 0.744), with net reclassiﬁcation index of –0.0062 (p ¼ 0.79).
CONCLUSIONS Appropriate training and unbiased assessment are needed when using SS in clinical decision making.
sSS and tertiles based on sSS showed poor discrimination among low, intermediate, and high-risk groups. However,
combining clinical factors with sSS retained the predictive performance of SS II. (SYNTAX Study: TAXUS Drug-Eluting
Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries; NCT00114972) (J Am Coll Cardiol
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AUC = area under the receiver
operating characteristic curves
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
cSS = ‘corelab’ SYNTAX score
HR = hazard ratio
MI = myocardial infarction
MACCE = major adverse
cardiac or cerebrovascular
event(s)
NRI = net reclassiﬁcation index
PCI = percutaneous coronary
intervention
SS = SYNTAX score
sSS = ‘site’ SYNTAX score
SYNTAX = SYNergy Between
PCI With TAXUS and Cardiac
Surgery
ULMCA = unprotected left
main coronary artery
3VD = 3-vessel disease
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FIGURE 1 Distribution and Individual Difference of the cSS
and the sSS
The mean SS was 28.7  11.4 for the corelab and 24.9  10.2 for
the site. cSS ¼ corelab SYNTAX score; SS ¼ SYNTAX score; sSS ¼
site SYNTAX score.I nterventional cardiologists and sur-geons in the SYNTAX (SYNergy BetweenPCI With TAXUS and Cardiac Surgery)
trial originally used the SYNTAX score (SS)
to extract objective information from the
coronary angiogram on the technical chal-
lenges posed by coronary anatomy to percu-
taneous coronary intervention (PCI) and
to facilitate discussions made by the heart
team (1). Subsequently, it became apparent
that the SS had a prognostic value to predict
short- and long-term outcomes (2–4). The
European and American revascularization
guidelines currently recommend the SS to
guide the heart term in decision making
(5–7). Moreover, high-risk SS category is a
key inclusion/exclusion criterion, imposed
by the U.S. Food and Drug Administration,
in several ongoing randomized controlled
trials, including EXCEL (Evaluation of Xience
Prime or Xience V versus Coronary Artery
Bypass Surgery for Effectiveness of Left
Main Revascularization), PARTNER-II (Place-
ment of AoRtic TraNscathetER Valves), andSURTAVI (Surgical Replacement and Transcatheter
Aortic Valve Implantation).SEE PAGE 433Knowledge of variability in calculating SS is of
paramount importance at a time of its widespread
use as a clinical decision-making tool. Risk stratiﬁ-
cation of patients in the SYNTAX trial was based on
“corelab” SS (cSS), which was calculated by the core
laboratory technicians blinded to the treatment
group. However, all sites participating in SYNTAX
also had a “site” SS (sSS) calculated by the site in-
vestigators, who at that time had no knowledge of
the prognostic signiﬁcance of the SS. The discrep-
ancy between cSS and sSS has been previously
highlighted in the SYNTAX trial (8). Recently, Gén-
éreux et al. (9) have demonstrated that interven-
tional cardiologists underestimate the number of
lesions, bifurcation, and the presence of small-vessel
disease, resulting in a lower SS than that reported
by the core laboratory technicians. The signiﬁcanceperial College London, London, United Kingdom. The SYNTAX t
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received February 19, 2014; revised manuscript received May 7,and prognostic value of the sSS in the SYNTAX trial
have not been evaluated.
This study aimed to examine the difference be-
tween the cSS and sSS in the randomized SYNTAX
trial and the prognostic performance of the sSS in
assessing outcomes among patients undergoing PCI
or coronary artery bypass grafting (CABG). We also
investigated the predictive performance of the SYN-
TAX II score, a recently developed risk score that
combines the anatomic SS with clinical variables to
predict long-term outcome of PCI and CABG when
calculated using either cSS or sSS.
METHODS
THE SYNTAX RANDOMIZED TRIAL. The SYNTAX trial
(NCT00114972) was a prospective, multicenter, ran-
domized trial to investigate subjects with unprotected
left main coronary artery (ULMCA) disease (isolated or
associated with 1-vessel, 2-vessel, or 3-vessel disease),
or de novo 3-vessel disease (3VD) (10). Eligible pa-
tients were randomized on a 1:1 ratio to CABG (n¼ 897)
or PCI with Taxus Express paclitaxel-eluting stent
(Boston Scientiﬁc Corporation, Natick, Massachusetts;
n ¼ 903) and followed up for 5 years. The primary
clinical endpoint of the SYNTAX trial was a compositerial was funded by Boston Scientiﬁc. Dr. Banning has
c, and Abbott Vascular. Dr. Dawkins is a full-time
sultant for Boston Scientiﬁc. All other authors have
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CENTRAL ILLUSTRATION Difference of the cSS and the sSS and Kaplan-Meier Curves for MACCE Using
Traditional (cSS-Based) Tertiles
(A) Distribution and individual difference of the cSS and the sSS. The absolute difference in cSS and sSS is 8.9  7.8. Cases on the left of the
y-axis had a higher sSS compared with the cSS; cases on the right of the y-axis had a lower sSS compared with cSS. (B) Kaplan-Meier cumulative
event curves for MACCE using traditional (cSS-based) tertiles. Kaplan-Meier curves are shown for MACCE between the PCI group and the CABG
group at 5-year follow-up by the sSS according to the traditional corelab tertiles in overall cohort (N¼ 1,800); sSS: 0 to 22 (n¼ 823); sSS: 23 to
32 (n ¼ 619); sSS:$33 (n ¼ 358). CABG¼ coronary artery bypass grafting; cSS¼ corelab SS; MACCE ¼major adverse cardiac or cerebrovascular
event(s); PCI ¼ percutaneous coronary intervention; sSS ¼ site SS.
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FIGURE 2 Correlation and Agreement Between the cSS and the sSS
(A) Relationship between the cSS (y-axis) and the sSS (x-axis), for all the patients in the
SYNTAX trial. Paired data were available for 1,789 of 1,800 subjects (99.4%). A total of
386 patients with high scores ($33) based on the cSS tertiles were calculated as low (0 to
22) or intermediate scores (23 to 32) by the investigate site. (B) Bland-Altman plots. The
measurements in cSS exceeded those of sSS by an average of 3.83 points (bias, as indicated
by the solid line). The limits of agreement (2 standard deviations [SDs], which describes
the range for 95% comparison points) ranged from –18.57 to þ26.23, represented by the
broken lines on the plot. This range is very wide from a clinical perspective, indicating poor
agreement existing between cSS and sSS. Abbreviations as in Figure 1.
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426of major adverse cardiac or cerebrovascular events
(MACCE) (e.g., death from any cause, stroke, myocar-
dial infarction [MI], or repeat revascularization) at
1-year follow-up. Secondary endpoints included the
incidence of MACCE and its components at 1-month, 6-
month, 3-year, and 5-year follow-up. An independent
clinical event committee comprising interventionalcardiologists, cardiac surgeons, and a neurologist
adjudicated all events.
THE SS CALCULATION. During the local heart team
meeting, the cardiac surgeon and interventional
cardiologist systematically reviewed the coronary
angiogram and speciﬁed the number of coronary le-
sions, along with their angiographic location and
characteristics. Diagnostic angiograms were scored
according to the SS algorithm (1). Each signiﬁcant
lesion (deﬁned as a diameter stenosis of$50% in$1.5-
mm vessels) is visually assessed and awarded a score
related to location and severity of the coronary lesion.
Additional points are given for total occlusion, bifur-
cation or trifurcation lesion, aorto-ostial lesion, severe
tortuosity, heavy calciﬁcation, thrombus, and
diffusely diseased segment. The sSS was calculated
during the local heart team meeting before randomi-
zation. Calculation of the cSS was done by an inde-
pendent core laboratory (Cardialysis BV, Rotterdam,
the Netherlands), blinded to treatment assignment.
THE SS II CALCULATION. The SS II has been previ-
ously generated by a combination of anatomic cSS
and clinical factors (age, creatinine clearance, left
ventricular ejection fraction, presence of ULMCA
disease, peripheral vascular disease, sex, and
chronic obstructive pulmonary disease) to predict 4-
year mortality risk after PCI or CABG (11). Using the
same model, we also have calculated SS II using the
sSS and using the sSS-based SS II to predict 4-year
mortality and make a treatment recommendation.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD and categorical variables
are shown as counts and percentages of the total.
Bland-Altman plots were used to compare the cSS and
sSS. The predictive values of anatomic cSS and sSS
were compared by evaluating differences in the area
under the receiver operating characteristic curves
(AUC) and standard errors using the Delong method.
The agreement between observed and predicted risks
for cSS and sSS was assessed with the Hosmer-
Lemeshow test. Comparisons of 5-year clinical out-
comes betweenCABG and PCIwere conductedwith the
Kaplan-Meier method and the log-rank tests. By Cox
regression analyses, the relative risks were shown as
hazard ratios (HRs) and 95% conﬁdence interval (CI).
Two patient subsets were predeﬁned in this study:
patients with ULMCA (with or without additional
vessel involvement), and those with 3VD in the
absence of left main coronary disease. To calculate the
SS II, multiple imputations (5) of missing values was
performed with an advanced imputation strategy,
which takes into account the correlation between all
potential predictors (11,12). The performance of the
TABLE 1 Risk Stratiﬁcation According to the Corelab SYNTAX Score Deﬁned Tertiles
Corelab SYNTAX Score
In
Total
Low
(≤22)
Median
(>22–≤32)
High
(>32)
Site SYNTAX score Low (#22) 409 262 145 816
Median (>22–#32) 122 254 241 617
High (>32) 43 94 219 356
In total 574 610 605 1,789
Values in bold represent concordant scores.
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427sSS-based SS II was evaluated using c-statistics (Har-
rell’s c-index) (13), calibration plots (14), reclassiﬁca-
tion table, and net reclassiﬁcation index (NRI) (15,16).
A probability value of less than 0.05 was considered
statistically signiﬁcant. All analyses were undertaken
using SPSS 20.0 (IBMCorporation, Armonk, NewYork).
RESULTS
SS BY THE CORE LABORATORY AND SITE. The cSS
was calculated in 99.4% (n ¼ 1,789) of patients,
missed in 0.6% (n ¼ 11) of patients. The sSS was
available in 100% (n ¼ 1,800). The cSS and sSS dis-
tributions are shown in Figure 1. The mean SS was
28.7  11.4 (range: 0 to 83) for the corelab and 24.9 
10.2 (range: 3 to 88) for the site. The mean difference
between cSS and sSS is 3.8  11.2, with an absolute
difference of 8.9  7.8 (Central Illustration). The sSS
was numerically identical to the cSS in 99 patients
(5.5%), underestimated in 1,106 (61.8%), and over-
estimated in 584 (32.7%). A signiﬁcant correlation
(r ¼ 0.49; p < 0.05) was found between the cSS and
sSS as shown in Figure 2A. However, Bland-Altman+
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FIGURE 3 Kaplan-Meier Cumulative Event Curves for MACCE Using
Kaplan-Meier curves are shown for MACCE between the PCI group and th
left main coronary artery disease subgroup (A) and the 3-vessel disease s
sSS: $33 (n ¼ 194). (B) Three-vessel disease subgroup (N ¼ 1,095); sSS:
grafting; MACCE ¼ major adverse cardiac or cerebrovascular event(s); Pplots showed that the limits of agreement (2 SDs
that describe the range for 95% comparison points)
were very wide (–18.57 to þ26.23 score), indicating a
poor agreement between the corelab and site calcu-
lated SS (Fig. 2B). Only 882 (49.3%) patients have
concordant scores according to the corelab SS-
deﬁned tertiles (Table 1).
CLINICAL ENDPOINTS USING sSS AND ESTABLISHED
SS TERTILES. Using the sSS, patients were grouped
into traditional SYNTAX tertiles of low (#22 score,+
+
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Traditional (cSS-Based) Tertiles
e CABG group at 5-year follow-up by the sSS according to the traditional corelab tertiles in the
ubgroup (B). (A) Left main subgroup (N ¼ 705); sSS: 0 to 22 (n ¼ 266); sSS: 23 to 32 (n ¼ 245);
0 to 22 (n ¼ 557); sSS: 23 to 32 (n ¼ 374); sSS: $33 (n ¼ 164). CABG ¼ coronary artery bypass
CI ¼ percutaneous coronary intervention; other abbreviations as in Figure 1.
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FIGURE 4 Kaplan-Meier Cumulative Event Curves for MACCE According to the New (sSS-Based) Tertiles
Kaplan-Meier curves are shown for MACCE between the PCI group and the CABG group at 5-year follow-up by the sSS according to the sSS-based new tertiles in overall
cohort (A), left main coronary artery disease subgroup (B), and 3-vessel disease subgroup (C). (A) Overall cohort (N ¼ 1,800); sSS: 0 to 19 (n ¼ 616); sSS: 20 to 27
(n ¼ 567); sSS: $28 (n ¼ 617). (B) Left main subgroup (N ¼ 705); sSS: 0 to 19 (n ¼ 211); sSS: 20 to 27 (n ¼ 182); sSS: $28 (n ¼ 312). (C) 3-vessel disease subgroup
(N ¼ 1,095); sSS: 0–19 (n ¼ 405); sSS: 20 to 27 (n ¼ 385); sSS: $28 (n ¼ 305). Abbreviations as in Figures 1 and 3.
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428n ¼ 823), intermediate (23 to 32 score, n ¼ 619), and
high ($33 score, n ¼ 358) scores (Central Illustration).
In the overall cohort, using the sSS, MACCE rates in
the low and intermediate tertiles were signiﬁcantly
higher in the PCI group than in the CABG group (p ¼
0.016, p ¼ 0.002, respectively); MACCE rate in the
high-score tertile was numerically but not statistically
higher with PCI compared with CABG (42.0% vs.
33.8%; p ¼ 0.105) (Central Illustration). In the ULMCA
subgroup, the 2 revascularization strategies had
similar MACCE rates during the 5-year follow-up
period (Fig. 3A). In the 3VD subgroup, the incidence
of MACCE was signiﬁcantly higher in the PCI groupthan in the CABG group in all tertiles (low, 35.3% vs.
25.9%; p ¼ 0.024; intermediate, 40.1% vs. 26.4%;
p ¼ 0.005; high, 46.1% vs. 24.3%; p ¼ 0.006) (Fig. 3B).
CLINICAL ENDPOINTS USING sSS ANDNEWTERTILES
BASED ON sSS. The actual tertiles according to the
sSS were low (#19 score, n ¼ 616), intermediate (20 to
27 score, n ¼ 567), and high ($28 score, n ¼ 617).
In the overall cohort, there was a trend toward
higher incidence of MACCE in the PCI group for low
scores, compared with the CABG group, but this dif-
ference was not statistically signiﬁcant (31.9% vs.
24.5%; p ¼ 0.054) (Fig. 4A). Risk of MACCE for inter-
mediate and high scores was signiﬁcantly increased
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FIGURE 5 Clinical Outcomes at 5-Year Follow-Up According to the New Tertiles
HR was calculated for CABG versus PCI at 5-year follow-up for each clinical endpoint according to the sSS-based new tertiles. CI ¼ conﬁdence
interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; other abbreviations as in Figures 1 and 3.
TABLE 2 Change in Treatment Recommendations*
According to the cSS and the sSS Models
Recommendations
sSS
TotalCABG or PCI CABG
cSS CABG or PCI 601 (33.6%) 168 (9.4%) 769 (43.0%)
CABG 459 (25.7%) 561 (31.3%) 1,020 (57.0%)
Total 1,060 (59.3%) 729 (40.7%) 1,789 (100%)
*Based on following recommendation: 3VD and SS #22–PCI or CABG; 3VD and
SS >22–CABG; ULMCA and #32–PCI or CABG; ULMCA and SS >32–CABG.
CABG ¼ coronary artery bypass grafting; cSS ¼ corelab SYNTAX score;
PCI ¼ percutaneous coronary intervention; sSS ¼ site SYNTAX score; ULMCA ¼
unprotected left main coronary artery; 3VD ¼ three-vessel disease.
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429with PCI versus CABG (39.5% vs. 29.5%; p ¼ 0.019;
43.0% vs. 31.4%; p ¼ 0.003, respectively) (Fig. 4A).
In the ULCMA disease subgroup (n ¼ 705),
MACCE rates were comparable and did not differ
signiﬁcantly between the 2 groups in each tertile
(Fig. 4B). In the 3VD subgroup (n ¼ 1,095), all groups
of low, intermediate, and high scores showed a
signiﬁcantly higher incidence of MACCE in the PCI
group than those in the CABG group at 5-year follow-
up (Fig. 4C).
There was no signiﬁcant difference in death,
stroke, and repeat revascularization between PCI
and CABG in the low tertiles, but a higher risk of MI
in the PCI group (p ¼ 0.002) (Fig. 5). In the interme-
diate tertiles, a signiﬁcantly higher proportion of
patients had repeat revascularization after PCI than
after CABG (HR, 2.65; 95% CI: 1.72 to 4.08; p < 0.001).
In the high tertiles, there was a signiﬁcantly higher
risk of death, MI, and repeat revascularization in the
PCI group, but an insigniﬁcantly lower risk of stroke
(p ¼ 0.177) (Fig. 5).
SUBSTANTIAL CHANGES IN TREATMENT DECISION
USING sSS. The predictive accuracy for 4-year mor-
tality was modest with cSS (AUC, 0.57; 95% CI: 0.54
to 0.59) and dropped further with sSS (AUC, 0.55; 95%
CI: 0.53 to 0.57). There was a poor agreement between
predicted and observed MACCE for the sSS and cSS,
using Hosmer-Lemeshow test (p ¼ 0.51, p ¼ 0.31,respectively). Furthermore, the treatment decision
based on SS tertile changed in more than one-third of
patients depending on whether cSS or sSS is used
(Table 2). For 9.4% of patients, the treatment decision
changed from PCI or CABG to CABG and for 25.7% the
treatment recommendation changed from CABG to
PCI or CABG.
MINIMAL CHANGES IN TREATMENT DECISION USING
sSS-BASED SS II. The sSS-based SS II had predictive
power similar to the cSS-based SS II (Harrell’s c-index:
0.736, 0.744, respectively). The calibration plots of
the sSS-based SS II showed a good agreement be-
tween the observed and predicted risk of mortality
(Fig. 6). The recommendations according to the
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FIGURE 6 Calibration Plots for the sSS-Based SS II
Calibration plots are shown for the sSS-based SS II model
predicting 4-year risk of mortality. The triangles indicate the
observed frequencies by quintile of predicted probabilities. Good
agreement was found between the observed and predicted
mortality for each group. K-M ¼ Kaplan-Meier; other abbrevia-
tions as in Figures 1 and 3.
TABLE 3 Recommen
Recommendation
cSS-based SS II CABG
CABG
PCI
Total
A total of 82.8% of patien
from PCI to CABG or vice v
Abbreviations as in Tabl
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430original cSS- and the sSS-based SS II models did not
warrant a change in revascularization strategy (from
PCI to CABG or CABG to PCI) in a large majority of
patients (Table 3). A large majority (83%) of patients
had the same recommendation: only eligible for
CABG (n ¼ 346; 19.2%); only eligible for PCI (n ¼ 76;
4.2%); or potentially amenable to both types of
revascularization (n ¼ 1,070; 59.4%). Patients with or
without events are reclassiﬁed by the sSS-based SS
II model, and their results are presented in Table 4
(NRI, –0.0062; p ¼ 0.79).
DISCUSSION
This post-hoc study of the SYNTAX randomized
trial has highlighted a signiﬁcant difference in thedations According to the cSS- and the sSS-Based SS II Models
s
sSS-Based SS II
TotalCABG CABG or PCI PCI
346 (19.2%) 173 (9.6%) 0 (0) 519 (28.8%)
or PCI 71 (3.9%) 1,070 (59.4%) 42 (2.3%) 1,183 (65.7%)
0 (0) 22 (1.2%) 76 (4.2%) 98 (5.4%)
417 (23.2%) 1,265 (70.3%) 118 (6.6%) 1,800 (100%)
ts (bold) had same recommendations. No recommendation was completely shifted
ersa.
e 2.anatomic SS calculated by the site and corelab and the
calculation of tertiles based on the sSS, which
compromised the ability of the SS to distinguish the
low-, intermediate-, and high-risk patients, especially
in the subgroup of 3VD. However, the prognostic
performance of SS II, which combines clinical vari-
ables with the SS, remained largely unaffected
whether the cSS or the sSS was used.
DIFFERENCES IN SITE AND CORELAB SS. There is a
signiﬁcant absolute difference in the SS calculated
by the site investigators and the core laboratory
analysts in the SYNTAX trial. Lack of advanced
training at each site is a plausible underlying reason
for this difference (9,17). Appropriate training can
signiﬁcantly reduce intraobserver and interobserver
variability of the SS calculation by interventional
cardiologists (9). A study comparing SS calculation
by interventional cardiologists and angiographic
core laboratory technicians has shown that inter-
observer agreement was initially poor among inter-
ventional cardiologists (k ¼ 0.33), but improved
substantially after advanced training (k ¼ 0.76).
Although SS is a continuous variable, in practice it
is used as a categorical variable, with 3 categories
determined by cSS cutoff values of 22 and 33. These
SS categories are being extensively used in clinical
practice and the guidelines to decide revasculariza-
tion strategy and in the ongoing randomized trials
(e.g., EXCEL, PARTNER-II, and SURTAVI) as inclu-
sion/exclusion criteria (18). However, our data high-
light the variability in calculating SS, which may have
a signiﬁcant impact on decision making and potential
consequences on patient outcomes based on the
choice of revascularization strategy.
OUTCOMES BASED ON sSS TERTILES. Using the
new tertiles (based on sSS) in the ULMCA disease
subgroup, there were no statistical differences in
MACCE rates between CABG and PCI in all tertiles.
These ﬁndings are consistent with studies demon-
strating comparable clinical outcomes for patients
with left main disease undergoing either PCI or CABG,
especially in low-risk patients (19,20). Park et al. (19)
have reported that PCI with sirolimus-eluting stents
was noninferior to CABG with respect to MACCE at 2
years in the treatment of patients with unprotected left
main coronary artery stenosis. Because the newer-
generation drug-eluting stents have been shown to
signiﬁcantly reduce the stent-related adverse events
(21,22), we speculate that the ongoing EXCEL trial will
show noninferiority of PCI for treating the majority of
patients with ULMCA disease.
It is noteworthy that for new site-based tertiles,
not only was a comparable MACCE in the low tertile
TABLE 4 Reclassiﬁcation Table Comparing 4-Year Mortality Risk Strata for
Original cSS- and the sSS-Based SS II
SS II Model
Using the cSS
SS II Model
Using the sSS
Total0% to 5% 5% to 10% $10%
0% to <5%
Persons included 600.0 (93.8) 40.0 (6.3) 0.0 (0.0) 640.0 (35.6)
Case patients 18.0 (77.9) 5.1 (22.1) 0.0 (0.0) 23.1 (12.2)
Control participants 582.0 (94.3) 34.9 (5.7) 0.0 (0.0) 616.9 (38.3)
Observed risk, %* 3.0 12.8 0.0
5% to <10%
Persons included 58.0 (10.2) 476.0 (83.4) 37.0 (6.5) 571.0 (31.7)
Case patients 5.0 (12.1) 35.2 (85.3) 1.1 (2.6) 41.3 (21.8)
Control participants 53.0 (10.0) 440.8 (83.2) 35.9 (6.8) 529.7 (32.9)
Observed risk, %* 8.6 7.4 2.9
$10%
Persons included 1.0 (0.2) 64.0 (10.9) 524.0 (89.0) 589.0 (32.7)
Case patients 0.0 (0.0) 7.1 (5.7) 117.9 (94.3) 125.0 (66.0)
Control participants 1.0 (0.2) 56.9 (12.3) 406.1 (87.5) 464.0 (28.8)
Observed risk, %* 0.0 11.1 22.5
Total
Persons included 659.0 (36.6) 580.0 (32.2) 561.0 (31.2) 1,800.0 (100.0)
Case patients 23.0 (12.1) 47.5 (25.1) 119.0 (62.8) 189.4 (100.0)
Control participants 636.0 (39.5) 532.6 (33.1) 442.0 (27.4) 1,610.6 (100.0)
Observed risk, %* 3.5 8.2 21.2 10.5
Values are n (%). In patients who died, the SS II model using the sSS reclassiﬁcation declined by 3.11%, whereas in
nonevent patients the reclassiﬁcation improved by 2.49%. The net reclassiﬁcation index was –0.0062 (p¼ 0.79).
*Observed risk at 4 years is estimated from the Kaplan-Meier curve by using observations in each cell.
Abbreviations as in Table 2.
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431but also the lowest incidence of MACCE was in the
intermediate tertile for both CABG and PCI groups.
This is somewhat similar to the ﬁndings in the
FREEDOM (Future Revascularization Evaluation in
Patients with Diabetes Mellitus: Optimal Management
of Multivessel Disease) trial, which suggested no
differential treatment effect according to the category
of the SS (#22 and $33) in patients with diabetes
and complex coronary artery disease (23). Indeed,
SS as an anatomic tool without taking into consider-
ation the clinical risk proﬁle of an individual patient is
suboptimal in predicting all the clinical outcomes.
Therefore, attempts have been made to combine
anatomic SS with clinical factors (e.g., Logistic
Clinical SS) to accurately predict individual patients’
risk (24).
sSS–BASED SS II. Recently proposed SS II, using
anatomic and clinical variables, has been shown to
signiﬁcantly improve decision making between CABG
and PCI compared with using anatomic SS alone (11).
In the present study, although the site investigators
frequently underestimated the sSS and using it
changed treatment decisions, its inﬂuence on the
overall capability of the SS II to predict prognosis and
guide decision making was limited. This suggests that
clinical variables were more powerful and counter-
acted any variability in calculating SS. It is plausible
that this superiority of SS II stems from the fact that it
used SS as a continuous variable and not as a cate-
gorical variable. This may circumvent the limitation,
outlined above, of the dependence of classiﬁcation
agreement in categorical variables on variability in
repeated measurements and frequency distribution
of the studied population.
CLINICAL IMPLICATION AND FUTURE PERSPECTIVE.
This study has many potential implications on clinical
practice. Revascularization guidelines strongly re-
commend that heart teams use SS for decision
making. However, it is essential to highlight that
adequate training of the staff calculating SS is vital.
It also may be possible in the near future to develop
automated algorithms and software to calculate SS
from coronary angiography or noninvasive multislice
computed tomography (25). Furthermore, it is note-
worthy that the uptake of anatomic SS in clinical
practice has been modest, despite recommendation
by the guidelines. It is probably attributable to vari-
ability in calculating SS and lack of clinical risk fac-
tors, which physicians generally believe to be equal
or more important. Finally, it is appropriate to sug-
gest that the heart teams use SS II, instead of
anatomic SS, for decision making to refer the patients
for either surgery or PCI.STUDY LIMITATIONS. This is a post-hoc study from
the SYNTAX randomized trial. At the time of the trial,
an online calculator for SS was not available, and the
trial sites may have had limited or varying experience
in calculating SS, which may have potential inﬂuence
on the observed variability.
CONCLUSIONS
The anatomic SS was frequently underestimated
by the site. Advanced training and unbiased as-
sessment is mandatory in clinical use of the SS.
The sSS and tertiles based on sSS showed poor
discrimination between low-, intermediate-, and
high-risk groups. However, combining clinical factors
with sSS retained the predictive performance of SS II.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Training
and unbiased assessment are needed to apply the
coronary anatomic SYNTAX score in clinical decision
making. Combining clinical factors with the SYNTAX
score (referred to as the SYNTAX-II score) reduces
variability.
TRANSLATIONAL OUTLOOK: The ongoing SYNTAX-II
study will prospectively evaluate the predictive value of
the SYNTAX-II score with regard to both short- and long-
term clinical outcomes as a guide to referral of patients
with coronary artery disease for either surgical or percu-
taneous revascularization.
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